The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

Conditions: Colorectal Cancer Interventions: Drug: Tas-102(Suyuan) combined with bevacizumab Sponsors: The Second Affiliated Hospital of Shandong First Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials